Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: Experience in Turkey

Simple item page
dc.contributor.authorSalihoğlu, Ayşe
dc.contributor.authorElverdi, Tuğrul
dc.contributor.authorKaradoğan, İhsan
dc.contributor.authorPaydaş, Semra
dc.contributor.authorÖzdemir, Evren
dc.contributor.authorErdem, Gökhan
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorAkyol, Gülşah
dc.contributor.authorKaynar, L.
dc.contributor.authorYeğin, Zeynep Arzu
dc.contributor.authorŞucak, Gülsan Türköz
dc.contributor.authorTopçuoğlu, Pervin
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorBirtaş, Elif
dc.contributor.authorGöker, Hakan
dc.contributor.authorBaşlar, Zafer
dc.contributor.authorFerhanoğlu, Burhan
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.tr_TR
dc.contributor.researcheridAAH-1854-2021tr_TR
dc.contributor.scopusid6603145040tr_TR
dc.date.accessioned2022-06-13T12:51:36Z
dc.date.available2022-06-13T12:51:36Z
dc.date.issued2015-03
dc.description.abstractCurrent treatment modalities can cure up to 70-80 % of patients with classical Hodgkin lymphoma. Approximately, 20-30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report the experience with brentuximab vedotin as single agent in 58 patients with relapsed or refractory Hodgkin lymphoma. The objective response rate was 63.5 % with 13 complete responders (26.5 %) among 49 patients evaluated at the early phase of treatment (2-5 cycles). Upon treatment prolongation (a parts per thousand yen6 cycles), 37 patients achieved a final objective response rate of 32.4 % with 21.6 % of complete and 10.8 % of partial response. Overall survival at 12 months was 70.6 %, and progression-free survival at 12 months was 32.8 %. Median overall survival could not be reached and median progression-free survival was 7 months. While the median duration of response was 9 months in the whole cohort, it was 11.5 months in the complete responders. Complete response rates in patients treated with > 3 chemotherapy regimens before brentuximab vedotin were significantly lower (p = 0.016). Fourteen patients were subsequently transplanted. In conclusion, brentuximab vedotin provided a bridge to transplantation in approximately one quarter of the patients. The declining response rates during the course of treatment suggest that transplantation should be implemented early during brentuximab vedotin treatment.en_US
dc.identifier.citationSalihoğlu, A. vd. (2015). "Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: Experience in Turkey". Annals of Hematology, 94(3), 415-420.en_US
dc.identifier.endpage420tr_TR
dc.identifier.issn0939-5555
dc.identifier.issue3tr_TR
dc.identifier.pubmed25231929tr_TR
dc.identifier.scopus2-s2.0-84925461571tr_TR
dc.identifier.startpage415tr_TR
dc.identifier.urihttps://doi.org/10.1007/s00277-014-2215-9
dc.identifier.urihttps://link.springer.com/article/10.1007/s00277-014-2215-9
dc.identifier.urihttp://hdl.handle.net/11452/27113
dc.identifier.volume94tr_TR
dc.identifier.wos000349225200007tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalAnnals of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBrentuximab vedotinen_US
dc.subjectHodgkin Lymphomaen_US
dc.subjectRefractoryen_US
dc.subjectRelapseden_US
dc.subjectTransplantationen_US
dc.subjectMalignanciesen_US
dc.subjectIntensityen_US
dc.subjectHematologyen_US
dc.subject.emtreeBrentuximab vedotinen_US
dc.subject.emtreeAntibody conjugateen_US
dc.subject.emtreecAC10-vcMMAEen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAlopeciaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer regressionen_US
dc.subject.emtreeConstipationen_US
dc.subject.emtreeCytopeniaen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeFatigueen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFeveren_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHodgkin diseaseen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLimb painen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMultiple cycle treatmenten_US
dc.subject.emtreeMuscle spasmen_US
dc.subject.emtreeMyalgiaen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeNeuropathyen_US
dc.subject.emtreeNeurotoxicityen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeOphthalmoplegiaen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePeripheral neuropathyen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreePruritusen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeTonic seizureen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeVomitingen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeDrug resistanceen_US
dc.subject.emtreeHodgkin diseaseen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeRecurrent diseaseen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTurkeyen_US
dc.subject.emtreeYoung adulten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshDrug resistance, neoplasmen_US
dc.subject.meshFemaleen_US
dc.subject.meshHodgkin diseaseen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoconjugatesen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshRecurrenceen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusBrentuximab Vedotin; Hodgkin's Disease; Refractory Materialsen_US
dc.subject.wosHematologyen_US
dc.titleBrentuximab vedotin for relapsed or refractory Hodgkin lymphoma: Experience in Turkeyen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Özkocaman_vd_2015.pdf
Size:
502.17 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus